Hepatitis C virus: A time for decisions. Who should be treated and when?
Open Access
- 1 January 2016
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pharmacology and Therapeutics
- Vol. 7 (1), 33-40
- https://doi.org/10.4292/wjgpt.v7.i1.33
Abstract
Cirrhosis is the most important risk factor for hepatocellular carcinoma (HCC) regardless of the etiology of cirrhosis. Compared to individuals who are anti-hepatitis C virus (HCV) seronegative, anti-HCV seropositive individuals have a greater mortality from both hepatic as well as nonhepatic disease processes. The aim of this paper is do describe the burden of HCV infection and consider treatment strategies to reduce HCV-related morbidity and mortality. The newly developed direct acting antiviral (DAA) therapies are associated with greater rates of drug compliance, fewer adverse effects, and appear not to be limited by the presence of a variety of factors that adversely affect the outcome of interferon-based therapies. Because of the cost of the current DAA, their use has been severely rationed by insurers as well as state and federal agencies to those with advanced fibrotic liver disease (Metavir fibrosis stage F3-F4). The rationale for such rationing is that many of those recognized as having the disease progress slowly over many years and will not develop advanced liver disease manifested as chronic hepatitis C, cirrhosis, and experience any of the multiple complications of liver disease to include HCC. This mitigation has a short sided view of the cost of treatment of hepatitis C related disease processes and ignores the long-term expenses of hepatitis C treatment consisting of the cost of treatment of hepatitis C, the management of cirrhosis with or without decompensation as well as the cost of treatment of HCC and liver transplantation. We believe that treatment should include all HCV infected patients including those with stage F0-F2 fibrosis with or without evidence of coexisting liver disease. Specifically, interferon (IFN)-free regimens with the current effective DAAs without liver staging requirements and including those without evidence of hepatic diseases but having recognized extrahepatic manifestations of HCV infection is projected to be the most cost-effective approach for treating HCV in all of its varied presentations. Early rather than later therapy of HCV infected individuals would be even more efficacious than waiting particularly if it includes all cases from F0-F4 hepatic disease. Timely therapy will reduce the number of individuals developing advanced liver disease, reduce the cost of treating these cases and more importantly, reduce the lifetime cost of treatment of those with any form of HCV related disease as well as HCV associated all - cause mortality. Importantly, HCV treatment regimens without any restrictions would result in a substantial reduction in health care expenditure and simultaneously reduce the number of infected individuals who are infecting others.Keywords
This publication has 57 references indexed in Scilit:
- Chronic hepatitis C: future treatmentClinical Pharmacology: Advances and Applications, 2014
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Two Distinct Functional Patterns of Hepatitis C Virus (HCV)-Specific T Cell Responses in Seronegative, Aviremic PatientsPLOS ONE, 2013
- Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology, 2012
- New perspectives in occult hepatitis C virus infectionWorld Journal of Gastroenterology, 2012
- HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co‐infected individualsJournal of Medical Virology, 2010
- Natural history and predictors of disease severity in chronic hepatitis CJournal of Hepatology, 2006
- Cellular Immune Responses Associated with Occult Hepatitis C Virus Infection of the LiverJournal of Virology, 2006
- Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infectionGut, 2005
- Evidences of Hepatitis C Virus Replication in Hepatocytes and Peripheral Blood Monocuclear Cells from Patients Negative for Viral RNA in SerumAmerican Journal of Infectious Diseases, 2005